|
Jan 21
|
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
|
|
Jan 21
|
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
|
|
Jan 17
|
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
|
|
Jan 16
|
Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application
|
|
Jan 16
|
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
|
|
Jan 2
|
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
|
|
Jun 21
|
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
|
May 11
|
Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 9
|
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
|
|
Apr 5
|
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 28
|
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 28
|
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
|
|
Jan 11
|
Seth Klarman's Exit from Atara Biotherapeutics Inc
|
|
Jan 11
|
Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding
|
|
Dec 20
|
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
|
|
Nov 29
|
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
|
|
Nov 8
|
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
|
|
Nov 5
|
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript
|